TOCAEUR

Forte Biosciences, Inc.

A clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, Forte Biosciences is focused on its main antibody candidate, FB102, meant to calm the immune system in conditions like vitiligo and celiac disease. Founded in 2017, its name echoes the Latin fortis, meaning "strong," and the Texas-based firm went public in 2020 through a reverse merger with Nasdaq-listed Tocagen. An earlier project, FB-401, was a topical eczema treatment made from live skin bacteria.